RE: Well well26 Mar 2018 11:37
Bignose- when you began by using the term orchestrated I thought you were going to go on to say that the switch to HK was to facilitate an Asian Pharma/entity to take a large stake. This may have proven more expensive and more problematic from a regulatory perspective if Ple had remained on AIM.
The counter argument was that it was done for access to RP�s cash pile, although a small Placing and /or combination of a loan from JM could have been a possible alternative. It is also interesting that since switching to HK no efforts whatsoever have been made to seek RP�s stated intention to be Hong Kong�s leading healthcare and life sciences investment enterprise.
I only disagree with you and JG to a point on HK investors waiting for sales. There will always be an element that does so, but likewise there will always be those that invest ahead of the curve in anticipation of future sales. Indeed in the case of pharma initial investments are always made ahead of sales and indeed P3 final approval, and generally many years ahead.
The UK launch was followed by 650 m shares traded the next day with no sales and 3 billion over the following two weeks. There must have been a very strong bid from somewhere to generate that level of activity and that would have pulled in traders / gamblers to trade around ,many of whom probably believed RP was still a mining company.
The last announcement was effectively the announcement of Euro 4 million of sales with a further � 36 m to follow. This is pretty good evidence that the rollout is happening and is generating sales with further sales highly likely to follow. So whilst some may sit on their hands all things being equal one would expect a big chunk of those that were interested pot the UK launch to have returned.
We have seen nothing whatsoever of the sort, which makes me even firmer in my view that a stake has been built and I accept the validity of your counter argument but given the share price action I don�t share it.
So, what�s holding up a bid for entire share capital? I can only speculate on two possibilities.
1) Waiting for initial Europe sales figures � I don�t really subscribe to this as if it is a substantial entity it will have built its stake for almost petty cash so not the end of the world if it had a 100% write down.
2) It is an Asian / China based entity that does not want to risk delaying/de-railing the FDA approval process in way shape or form so it is waiting patiently for the FDA green light for Fortacin before making its move. This will of course make the remaining shares to acquire far more expensive.
It is also very strange that given the massive volumes post UK launch that we don�t have a single disclosable interest registered with the HKEX.
I don�t know what JG does in HK one way or another, but given the story of the next Viagra, whether you believe that or not I would expect the broker commu
Sign In
Follow the stocks
